ZENTIVA A SANOFI COMPANY Corporate Presentation
SANOFI A global healthcare leader, focused on patients needs
SANOFI A global integrated healthcare leader, focused on patients needs CORPORATE PRESENTATION 2013
OUR GROUP SANOFI AT A GLANCE more than 110,000 Employees (1) present in 100 countries A diversified offer of medicines, vaccines and innovative therapeutic solutions 34.9bn in sales in 2012 112 industrial Sites in 40 countries We are a global integrated healthcare company engaged in the research, development, manufacturing and marketing of healthcare products. (1) As of December 31, 2012
OUR GROUP OUR HERITAGE A long tradition in health BMP Sunstone, Medley, Merial, Nepentes, Zentiva, Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha Biotechnics 2008-2010 Sanofi-aventis 2004 Genzyme 2011 Aventis 1999 Sanofi Pasteur 2004 Sanofi-Synthélabo 1999 Marion 1950 Hoechst Marion Roussel 1997 Rorer 1910 Rhône-Poulenc Rorer 1990 Synthélabo 1970 Sanofi 1973 Roussel 1911 Connaught 1922 Institut Mérieux 1897 Delagrange 1931 Delalande 1924 Sterling 1901 Chinoin 1919 Clin Midy 1971 Hoechst 1863 Wittman & Poulenc 1860 Robert & Carrière 1901 Dausse 1834 Midy 1718
KEYS FIGURES NET SALES (in million euros) TOTAL SALES OF GROWTH PLATFORMS (in million euros) TOTAL SALES BY GEOGRAPHICAL ZONE (in million euros) 32,367 33,389 34,947 Animal health 2,179 Genzyme 1,785 Other products 611 Western Europe 8,335 Other countries 4,594 Emerging markets 11,145 Consumer Health care 3,008 Emerging markets 11,145 2010 2011 2012 Vaccines 3,897 Diabetes 5,782 United States 10,873
KEYS FIGURES Our global workforce: more than 110,000 employees throughout the world EMPLOYEES BY GEOGRAPHIC ZONE North America 18,994 Other countries 36,715 France 28,111 Europe (excl. France) 28,154 CORPORATE PRESENTATION 2013 7
KEYS FIGURES PRESENT IN 100 COUNTRIES 82 sites pharmaceutics 13 sites vaccines 112 Industrial sites in 40 countries 17 sites animal health 10 sites in Europe 7 sites in North America 1 site in Asia 18 R&D sites worldwide
OUR GROWTH PLATFORMS Emerging markets Diabetes solutions Vaccines Consumer Healthcare Animal Health New Genzyme Other Innovative Products
INNOVATION IN R&D ACCELERATE INNOVATION FOR PATIENTS We have to be where the pathologies and the patients needs are. We act as one to discover and develop therapies that prevent, treat and cure disease. We are focused on vaccines and 7 key therapeutic areas: 64 projects and vaccines under clinical development 18 Potential launches between 2012 and 2015 Multiple Sclerosis Diabetes Oncology Rare Diseases Cardio-Metabolic Diseases Immunology
ZENTIVA AT A GLANCE
Zentiva, a Sanofi company is an international leader that develops, produces and distributes high quality affordable generic medicines that improve and prolong the lives of more patients in more countries
Our vision We aim to exceed customer expectations by reliably providing high quality generic products with superior service. We deliver sustainable growth in constantly evolving, competitive markets, thereby creating value for all of our stakeholders, including healthcare systems. We empower and develop our people to be entrepreneurial and performance-driven, thus shaping our company s successful future. Together we are diverse, engaged, and stronger, making Zentiva a great place to work.
Our brand Zentiva is the key element of Sanofi s Gx business Zentiva emerged in 2003 as combination of Czech brand Léčiva with Slovak s Slovakofarma. Since 2011 the Zentiva brand is the name for all of Sanofi s generics across its markets in Europe. In 2013, Zentiva entres new markets in Africa and Middle East. Zentiva brand values are: modern, high quality, affordability.
Our markets Zentiva is the key element of Sanofi s Gx business Zentiva Operates in more than 50 markets in Europe, Africa and Middle East. Sales EUR 1 billion in 2012. Reaches out to a population of over 1 billion patients. Produces annually 500 million packages of Zentiva products. More than 250 products launched in 2012. Prague headquarters is the decision making centre for portfolio strategy, development and regulatory processes for Sanofi Gx business worldwide.
Our market position Zentiva is the 3 rd biggest Gx player* in Mio. EUR, 2012 1 2 TEVA SANDOZ 2.507 2.433 3 ZENTIVA 1.204 4 5 6 7 8 9 10 MYLAN 1.147 BIOGARAN/EGIS 972 STADA 963 KRKA 527 GEDEON RICHTER 404 MENARINI 362 ACTAVIS 358 * Includes only countries where Zentiva is present; IMS ex manufacturer sales 2012
Our origins Zentiva has a long history of producing high quality pharmaceuticals Business Rationalisation Positioned for Regional Growth Leading CEE Player Expanding Internationally Zentiva recognized as Generics Business of Sanofi Group Zentiva traces its origins back to the At the Black Eagle Pharmacy in Prague Management buyout Acquisition of Slovakofarma + Launch of the Zentiva corporate brand Zentiva acquired Sicomed, the leading generics company in Romania Zentiva combined with Sanofi Zentiva leads global Sanofi s Gx portfolio strategy and development 1488 1930 1998 2000 2003 2004 2005 2007 2009 2011 2012 2013 Manufacturing beings at Prague site Zentiva listed on the Prague and London Stock Exchanges Zentiva acquired Eczacibaci Generic Pharmaceuticals, a leading pharmaceutical company in Turkey Zentiva entered Western Europe through rebranding of Winthrop and Helvepharm Zentiva enters new markets in Africa and Middle East
Our therapeutic areas Zentiva sales *in M ** by ATC1 N CNS 1283 C CARDIO A ALIM J ANTI-INF M MUSC-SKEL R RESPIR L ONCO G SEX HORM 2011 B BLOOD H SYST HORM OTHER * Includes only countries where Zentiva is present ** IMS ex manufacturer sales MAT Q3 2011
Our Industrial Affairs We are one of largest producers of affordable medicines based in Europe TR / Lüleburgaz DP Development and Production HC: 816 people Munich Prague Bucharest Lüleburgaz DE / Munich Respiratory Development HC: 72 people CZ / Prague API and DP Development, Pharma Production HC: 882 people RO / Bucharest Pharma Production HC: 399 people DP: drug product API: Active pharmaceutical ingredient
Our people People are our biggest competitive advantage Zentiva success is built on our more than 6,000 people. 4,000 commercial operations 2,200 Industrial affairs and headquarters We support diversity among our teams. Our values of respect and solidarity are reflected in Zentiva policies and lived through our operations.
Our responsibility Zentiva sustainability approach places the patient at the heart of its business conduct. This approach is based on four key areas: P A T I E N T E T H I C S P E O P L E P L A N E T
We are ZENTIVA Zentiva Group a.s. // U Kabelovny 130 // 102 37 Prague 10 // Czech Republic Phone: (+420) 267 241 111 // E-mail: zentiva@zentiva.com // www.zentiva.com